Insulet Corp (PODD)
183.80
-3.47
(-1.85%)
USD |
NASDAQ |
May 20, 15:49
Insulet Cash from Operations (Annual): 145.70M for Dec. 31, 2023
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 145.70M |
| December 31, 2022 | 119.00M |
| December 31, 2021 | -68.10M |
| December 31, 2020 | 84.00M |
| December 31, 2019 | 98.40M |
| December 31, 2018 | 35.90M |
| December 31, 2017 | 41.30M |
| December 31, 2016 | 15.91M |
| December 31, 2015 | -12.55M |
| December 31, 2014 | 8.92M |
| Date | Value |
|---|---|
| December 31, 2013 | 3.348M |
| December 31, 2012 | -29.06M |
| December 31, 2011 | -25.45M |
| December 31, 2010 | -35.62M |
| December 31, 2009 | -49.32M |
| December 31, 2008 | -82.61M |
| December 31, 2007 | -50.37M |
| December 31, 2006 | -31.82M |
| December 31, 2005 | -20.32M |
| December 31, 2004 | -13.06M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Annual) Range, Past 5 Years
-68.10M
Minimum
2021
145.70M
Maximum
2023
75.80M
Average
98.40M
Median
2019
Cash from Operations (Annual) Benchmarks
| Stryker Corp | 3.711B |
| Tandem Diabetes Care Inc | -31.81M |
| Abbott Laboratories | 7.261B |
| ResMed Inc | 693.30M |
| Integra Lifesciences Holdings Corp | 139.96M |